Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Genzyme, a Sanofi Company
end-point Efficacy: event-free survival (EFS)
Age
45–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Post menopausal women with locally advanced or metastatic breast cancer
Patients may have either measurable or non-measurable disease, as defined by RECIST criteria
One previous hormone therapy or one previous chemotherapy for advanced disease are allowed (patients who have stable but evident disease after chemotherapy are eligible)
estrogen receptor positive ER+ and/or progesterone receptor positive PR+ on primary or secondary tumour
You may not be if
Hormone receptor negative tumours (ER and PR negative)
Presence of life-threatening metastatic visceral disease
Significant cardiovascular event (e.g. myocardial infarction, superior vena cava \[SVC\] syndrome, New York Heart Association \[NYHA\] classification of heart disease ³2) within 3 months before entry, or presence of cardiac disease that in the opinion of
History of arrhythmia or QTc with Bazett's correction unmeasurable or ≥ 480 msec on screening ECG
Clareo Health | ZACtima FASlodex Trial in Postmenopausal Advance Breast Cancer Patients Instead of ZACtima FASlodex Trial
